Precancerous melanoma is not a single, sharply defined diagnosis but a term used loosely to describe skin lesions that sit somewhere on the path between a normal mole and a full-blown invasive melanoma. In clinical practice, two types of lesion fall under this umbrella: dysplastic nevi (atypical moles) and melanoma in situ, which is a collection of cancerous melanocytes that has not yet broken through the skin’s outermost layer. The distinction matters because these two categories carry very different levels of urgency, and understanding what each looks like can influence how quickly you seek evaluation.
The Spectrum From Atypical Mole to Melanoma in Situ
Skin cells that produce pigment, called melanocytes, can accumulate genetic damage over time. When that damage produces a mole with unusual features under a microscope, pathologists call it a dysplastic nevus. When the damage progresses further and the cells start behaving like cancer cells but remain confined to the epidermis (the thin outer skin layer), the diagnosis becomes melanoma in situ. Only when those cells push through the basement membrane into deeper tissue does the lesion become invasive melanoma.
Dysplastic nevi occupy an awkward position in dermatology. They are considered risk markers for melanoma more than direct stepping stones to it, because any single dysplastic nevus rarely transforms into melanoma. A large review noted that the primary importance of dysplastic nevi lies in their association with elevated melanoma risk rather than their role as obligate precursors, since individual transformation is rare.1PubMed Central. Dysplastic nevi and melanoma In other words, having many atypical moles signals that your skin is prone to melanoma, but the specific mole your dermatologist flags may never be the one that becomes dangerous.
Melanoma in situ, by contrast, is already cancer by cellular criteria. The cells look malignant under a microscope and carry many of the same genetic mutations found in invasive melanoma. What keeps it in the “precancerous” or “pre-invasive” category is location: the abnormal cells have not yet crossed into the dermis, so they cannot spread to lymph nodes or other organs. Genetic studies have shown that mutations associated with invasive melanoma, including changes in a gene region called the TERT promoter, appear in roughly three-quarters of intermediate lesions and melanoma in situ, indicating that these mutations arise earlier in the disease process than researchers once expected.2PubMed. The Genetic Evolution of Melanoma from Precursor Lesions
How Dysplastic Nevi Look on the Skin
A dysplastic nevus typically looks like a mole that breaks one or more of the rules you would expect from a normal, round, evenly colored freckle. These moles tend to be larger than ordinary ones and may have an irregular or fading border, where the pigment seems to bleed into surrounding skin rather than stopping cleanly. The color is often uneven: you might see shades of tan, brown, and pink within the same lesion. They can be flat or slightly raised, and they sometimes have a fried-egg appearance, with a darker center and a lighter rim.
Pathologists now grade dysplastic nevi on a spectrum from low-grade to high-grade. A recent update to grading criteria uses a framework that distinguishes low-grade from high-grade based on how enlarged and irregular the melanocyte nuclei appear, along with how disorganized the architecture of the lesion is.3International Journal of Dermatology. Grading Melanocytic Dysplasia: Updated Histopathologic Criteria Low-grade dysplastic nevi are generally monitored, while high-grade ones are often excised because the line between severe dysplasia and melanoma in situ can be genuinely blurry, even for experienced pathologists.
What Melanoma in Situ Looks Like
Melanoma in situ can appear as a flat, irregularly shaped patch of pigment. The color may range from light brown to very dark brown or black, and it often shows multiple shades within a single lesion. Borders are frequently jagged or notched. Unlike a raised mole, melanoma in situ tends to spread outward across the skin surface, sometimes growing slowly over years before anyone notices a change.
One specific subtype, called lentigo maligna, appears almost exclusively on chronically sun-exposed skin, particularly the face, scalp, and neck of middle-aged and older adults. It typically presents as a flat, irregularly pigmented patch that may look like a large age spot or sun spot, and it is considered the in situ phase of a cancer called lentigo maligna melanoma.4PubMed Central. Diagnosis and management of lentigo maligna: a review This is one of the trickier precancerous melanoma types because it closely resembles a benign sunspot, grows very slowly, and can become quite large before a clinician or patient suspects anything.
Dermoscopy, a technique where a clinician examines a lesion through a magnifying lens with polarized light, can reveal features invisible to the naked eye. Studies have found that two dermoscopic features are particularly strong indicators of melanoma in situ when comparing it to benign moles: irregular patches of very dark pigment within the lesion and prominent skin markings (the normal furrow lines of the skin becoming more visible within the lesion’s pigment). The presence of irregular dark areas made a lesion about four times more likely to be melanoma in situ.5JAMA Dermatology. Accuracy of Dermoscopic Criteria for the Diagnosis of Melanoma In Situ
The ABCDE Rule and Why It Has Limits
You have probably seen the ABCDE mnemonic: Asymmetry, Border irregularity, Color variation, Diameter greater than 6 millimeters, and Evolution (any change over time). This checklist has been promoted globally for decades as a way for ordinary people to flag suspicious moles.6PubMed. Early detection of melanoma: reviewing the ABCDEs It is a useful starting framework, but its reliability in untrained hands is questionable.
An experimental study asked non-expert volunteers to score a set of lesions, including benign moles, dysplastic nevi, melanomas, and a common benign growth called seborrheic keratosis, using the ABC criteria. The results were discouraging: untrained people could not reliably use asymmetry, border irregularity, or color variation to distinguish dangerous lesions from harmless ones.7PubMed Central. Novice identification of melanoma: not quite as straightforward as the ABCDs The problem is that many benign lesions also look asymmetric or have irregular color, while some early melanomas are small, round, and evenly pigmented. The ABCDE criteria work better as a prompt to see a dermatologist than as a self-diagnostic tool.
A complementary approach that performs surprisingly well is the “ugly duckling” sign: instead of analyzing one mole in isolation, you compare it to the pattern of all your other moles. The mole that looks different from the rest, the one that does not match the family, is the one worth checking. In one study, all five melanomas in a test set were identified as “different” by at least 85% of observers, while only about 2% of benign lesions triggered the same reaction.8JAMA Dermatology. The “Ugly Duckling” Sign: Agreement Between Observers This holistic comparison seems to tap into pattern recognition that outperforms rigid criteria, and it works for both experts and laypeople.
The Diagnostic Pitfall of Amelanotic Lesions
One scenario that makes precancerous and early melanoma particularly dangerous is when the lesion lacks pigment. Amelanotic melanoma contains little or no visible color and can look like a pink bump, a flesh-toned patch, or even a scar-like area. Because people expect melanoma to be dark brown or black, these pale lesions are frequently mistaken for something harmless. Clinical diagnosis of amelanotic melanoma has notably lower accuracy than for pigmented versions, though dermoscopy improves things considerably. One study found that dermoscopic examination had a sensitivity of 89% for amelanotic melanoma, compared with only 65% for clinical inspection alone. In truly amelanotic cases, abnormal blood vessel patterns visible under dermoscopy were the only reliable clue.9PubMed. Amelanotic/hypomelanotic melanoma: clinical and dermoscopic features
This is worth knowing because it undermines the assumption that color change is always the warning sign. If you have a new, persistent pinkish spot that does not heal, or a firm bump that appeared out of nowhere and looks unlike your other skin features, it is reasonable to have it checked even though it does not fit the typical melanoma profile.
Sunburn, Sun Exposure, and Risk
Ultraviolet radiation is the dominant environmental driver of melanocytic damage. Genetic analysis of melanoma’s evolution from benign precursor to cancer consistently shows a strong UV damage signature at every stage, from the earliest benign lesion through to invasive disease.2PubMed. The Genetic Evolution of Melanoma from Precursor Lesions But the relationship between sun exposure and melanoma risk is not as straightforward as “more sun equals more risk.”
A large study examining the effects of painful sunburns and cumulative lifetime sun exposure found an interesting split. Sunburns before age 20 were associated with increased risk of melanoma and its precursors, with about a 40-50% elevated risk for melanoma and for atypical nevi. However, total lifetime sun exposure was actually associated with a lower risk of melanoma, even though it did not reduce the number of precursor moles on the skin.10PubMed. The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer The takeaway is that intense, intermittent burns, especially in youth, are a bigger red flag for melanoma than steady, moderate sun exposure over a lifetime. This partly explains why melanoma tends to appear on areas that get burned occasionally (the back, for instance) rather than areas with constant, year-round exposure.
Why Skin Color Complicates Detection
Much of the visual guidance about melanoma, including most reference images in textbooks and patient education materials, is based on light-skinned populations. In people with darker skin tones, melanoma is less common overall but tends to be diagnosed later and at a more advanced stage. Pigmented skin can also complicate the physical examination for other skin cancers. Research has noted that in people of color, over half of basal cell carcinomas contain pigmentation that obscures the characteristic features clinicians are trained to look for.11PubMed Central. Skin Cancer Concerns in People of Color: Risk Factors and Prevention
Melanoma in darker-skinned individuals also tends to appear in different locations. Rather than showing up on sun-exposed areas of the trunk or limbs, it more commonly develops on the palms, soles of the feet, and under nails. These acral locations are easy to overlook and rarely get examined during routine skin checks. Awareness that precancerous melanoma can look different and show up in unexpected places depending on your skin type is an important gap in public understanding.
Treatment of Melanoma in Situ
Because melanoma in situ has not invaded deeper tissue, treatment is straightforward in principle: cut it out with enough surrounding margin to ensure nothing is left behind. In practice, the definition of “enough” depends on the lesion’s size, location, and subtype.
Standard excision with a 5-millimeter margin of normal-looking skin is considered appropriate for small, well-defined melanoma in situ on the trunk or limbs. But that margin is often insufficient for the lentigo maligna subtype or for lesions on the head and neck, where the cancer can extend invisibly beyond what the eye can see. Studies have shown that 5-millimeter margins lead to recurrence rates of about 8-20% for lentigo maligna, because unseen cancerous cells frequently extend further than expected.12International Journal of Dermatology. Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery
For ill-defined or larger lesions, guidelines suggest wider margins of 10 to 15 millimeters, and some surgeons opt for Mohs surgery or a similar technique that examines the entire edge of the removed tissue under a microscope before closing the wound.13PubMed Central. Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations This margin-checking approach brings recurrence rates down substantially, to roughly 0.5-3%, and is particularly valuable on the face, where removing large amounts of skin has cosmetic and functional consequences.14PubMed. Mohs surgery for the treatment of melanoma in situ: a review
Topical treatments like imiquimod cream have been tried for melanoma in situ, but cure rates are relatively low, and there is a risk that an unrecognized invasive component lurks beneath a lesion that looked purely in situ on a small biopsy. Radiation therapy remains a second-line option, reserved for patients who cannot undergo surgery.
Monitoring if You Are High Risk
If you have a personal or family history of melanoma, a large number of atypical moles, or a known genetic predisposition, the monitoring schedule is more aggressive than standard annual skin checks. Experts recommend skin examinations every three to six months for high-risk individuals, including inspection of the scalp, mouth, and genital areas. Total body photography, where baseline photographs of your entire skin surface are taken so that any new or changed lesion can be spotted at the next visit, is a useful tool for tracking subtle changes over time.15PubMed Central. Hereditary melanoma: Update on syndromes and management
For families with an identified genetic mutation affecting the CDKN2A gene, a tumor suppressor linked to hereditary melanoma, screening should begin around puberty, with lower thresholds for biopsy of anything that looks suspicious. Genetic counseling and testing can help clarify who in a family carries the mutation and needs this level of surveillance.16Australasian Journal of Plastic Surgery. The management of hereditary melanoma, FAMMM syndrome and germline CDKN2A mutations: a narrative review
The Overdiagnosis Question
An uncomfortable reality in melanoma medicine is that the number of melanoma in situ diagnoses has climbed steeply in recent decades, while the death rate from melanoma has remained relatively flat. This pattern has led some researchers to question whether a meaningful fraction of these diagnoses represent overdiagnosis: the detection and treatment of lesions that would never have become life-threatening. A review of this trend noted that screening can detect melanoma earlier but is likely associated with overdiagnosis and overdetection, which may lead to unnecessary procedures with little survival benefit.17PubMed Central. Incidence of in Situ vs Invasive Melanoma: Testing the “Obligate Precursor” Hypothesis
Supporting this concern, the average age at diagnosis for melanoma in situ is often the same as or even older than for invasive melanoma, which does not fit neatly with the idea that in situ disease always precedes invasive disease. If most in situ lesions were caught “on their way” to becoming invasive, you would expect them to be diagnosed in younger patients. The fact that many are found in older people suggests a substantial proportion grow very slowly and may never progress within a patient’s lifetime.
This does not mean melanoma in situ should be ignored. Some of these lesions clearly do progress, and there is no reliable way to tell which ones will and which ones will not. But the overdiagnosis debate explains why some dermatologists are cautious about aggressive population-wide skin screening programs and why some advocate for watchful waiting in certain low-risk scenarios rather than immediate wide excision of every borderline lesion.
Smartphone Apps and AI-Assisted Screening
Consumer-facing smartphone applications that use artificial intelligence to evaluate photos of skin lesions are becoming widely available. A prospective study testing one such app found that its AI component achieved a sensitivity of about 83% and specificity of about 77% for detecting skin cancer, with performance improving when a dermatologist also reviewed the images remotely. However, the system was notably less sensitive for melanocytic lesions (roughly 71%) than for other skin cancers, and in user hands, only about 29% of image captures were successful enough for the algorithm to analyze.18PubMed. Artificial intelligence-based smartphone application for skin cancer detection: a prospective diagnostic accuracy study
These tools may have a future role in triaging who needs to see a dermatologist, but they are not reliable enough to replace a clinical examination, especially for early melanocytic lesions where the visual differences can be extremely subtle. The low image-capture success rate alone suggests that the gap between a controlled research setting and real-world use is still wide. If you are concerned about a lesion, an in-person evaluation with dermoscopy remains the standard you should aim for.